These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 9267669)
21. High-dose chemotherapy, autologous bone marrow or stem cell transplantation and post-transplant consolidation chemotherapy in patients with advanced breast cancer. Tallman MS; Rademaker AW; Jahnke L; Brown SG; Bauman A; Mangan C; Kelly C; Rubin H; Kies MS; Shaw J; Kiel K; Gordon LI; Gradishar WJ; Winter JN Bone Marrow Transplant; 1997 Nov; 20(9):721-9. PubMed ID: 9384473 [TBL] [Abstract][Full Text] [Related]
22. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes. Wheeler C; Eickhoff C; Elias A; Ibrahim J; Ayash L; McCauley M; Mauch P; Schwartz G; Eder JP; Mazanet R; Ferrara J; Rimm IJ; Guinan E; Bierer B; Gilliland G; Churchill WH; Ault K; Parsons S; Antman K; Schnipper L; Tepler I; Gaynes L; Frei E; Kadin M; Antin J Biol Blood Marrow Transplant; 1997 Jun; 3(2):98-106. PubMed ID: 9267670 [TBL] [Abstract][Full Text] [Related]
23. [Combination of high-dose chemotherapy with autologous hematopoietic stem cell transplantation for recurrent and high-risk breast cancer: a pilot study]. Shi Y; Pan F; Han X Zhonghua Yi Xue Za Zhi; 1999 Dec; 79(12):890-3. PubMed ID: 11715500 [TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy. Mohr M; Hilgenfeld E; Fietz T; Hoppe B; Koenigsmann M; Hoffmann M; Knauf WU; Cassens U; Sibrowski W; Kienast J; Thiel E; Berdel WE Clin Cancer Res; 1999 May; 5(5):1035-40. PubMed ID: 10353736 [TBL] [Abstract][Full Text] [Related]
25. A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant. Nieto Y; Cagnoni PJ; Shpall EJ; Xu X; Murphy J; Vredenburgh J; Chao NJ; Bearman SI; Jones RB Clin Cancer Res; 1999 Nov; 5(11):3425-31. PubMed ID: 10589754 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and toxicity of sequential high-dose therapy with peripheral blood stem cell support in patients with high-risk breast cancer. Hohaus S; Wallwiener D; Martin S; Voso MT; Huober J; Fersis N; Bastert G; Haas R Semin Oncol; 1998 Apr; 25(2 Suppl 4):7-11; discussion 45-8. PubMed ID: 9578056 [TBL] [Abstract][Full Text] [Related]
27. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. Zander AR; Kröger N; Schmoor C; Krüger W; Möbus V; Frickhofen N; Metzner B; Schultze W; Berdel WE; Koenigsmann M; Thiel E; Wandt H; Possinger K; Trümper L; Kreienberg R; Carstensen M; Schmidt EH; Jänicke F; Schumacher M; Jonat W J Clin Oncol; 2004 Jun; 22(12):2273-83. PubMed ID: 15111618 [TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929 [TBL] [Abstract][Full Text] [Related]
29. The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer. Peters WP; Ross M; Vredenburgh JJ; Hussein A; Rubin P; Dukelow K; Cavanaugh C; Beauvais R; Kasprzak S Semin Oncol; 1994 Aug; 21(4 Suppl 7):25-31. PubMed ID: 7916487 [TBL] [Abstract][Full Text] [Related]
30. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer. Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899 [TBL] [Abstract][Full Text] [Related]
31. Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer. Klein JL; Rey PM; Dansey RD; Karanes C; Du W; Abella E; Cassells L; Hamm C; Peters WP; Baynes RD Bone Marrow Transplant; 2000 May; 25(10):1047-52. PubMed ID: 10828864 [TBL] [Abstract][Full Text] [Related]
32. Detection of tumor cells in the bone marrow of stage IV breast cancer patients receiving high-dose chemotherapy: the role of induction chemotherapy. Vredenburgh JJ; Peters WP; Rosner G; DeSombre K; Johnston WW; Kamel A; Wu K; Bast RC Bone Marrow Transplant; 1995 Dec; 16(6):815-21. PubMed ID: 8750275 [TBL] [Abstract][Full Text] [Related]
33. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95. ; Basser RL; O'Neill A; Martinelli G; Green MD; Peccatori F; Cinieri S; Coates AS; Gelber RD; Aebi S; Castiglione-Gertsch M; Viale G; Price KN; Goldhirsch A J Clin Oncol; 2006 Jan; 24(3):370-8. PubMed ID: 16421418 [TBL] [Abstract][Full Text] [Related]
34. [High-dose chemotherapy with autologous peripheral blood stem cell transplantation support in a patient with breast cancer metastasis to bone marrow: immunocytochemical monitoring of cancer-cell contamination]. Uno H; Fujita M; Hino N; Nakagawa H; Miyagawa H; Aoki J; Taniyama K; Sasaki N Rinsho Ketsueki; 1999 Jul; 40(7):556-62. PubMed ID: 10483138 [TBL] [Abstract][Full Text] [Related]
35. Decrease in tumor cell contamination and progenitor cell yield in leukapheresis products after consecutive cycles of chemotherapy for breast cancer treatment. Glück S; Ross AA; Layton TJ; Ostrander AB; Goldstein LC; Porter K; Ho AD Biol Blood Marrow Transplant; 1997 Dec; 3(6):316-23. PubMed ID: 9502299 [TBL] [Abstract][Full Text] [Related]
36. Early intensive and myeloablative adjuvant chemotherapy in women with high-risk breast cancer. Wörmann B; Meden H; Riggert J; Humpe A; Wulf G; Koch B; Köhler M; Kuhn W; Hiddemann W Anticancer Res; 1998; 18(3C):2237-41. PubMed ID: 9703793 [TBL] [Abstract][Full Text] [Related]
37. Micrometastases in apheresis products predict shorter progression-free and overall survival in patients with breast cancer undergoing high-dose chemotherapy (HDCT) and autologous blood stem cell transplantation (ABSCT). Syme R; Stewart D; Rodriguez-Galvez M; Luider J; Auer Y; Klassen J; Morris D; Brown C; Russell J; Glück S Bone Marrow Transplant; 2003 Aug; 32(3):307-11. PubMed ID: 12858203 [TBL] [Abstract][Full Text] [Related]
38. [High-dose chemotherapy in breast cancer. Promising results in combination with stem cell support]. Ljungman P; Björkstrand B; Gahrton G; Nordenström J; Shanwell A; Glas U; Rotstein S; Rutqvist LE; Wilking N Lakartidningen; 1995 Mar; 92(9):849, 851-3. PubMed ID: 7885111 [TBL] [Abstract][Full Text] [Related]
39. Treatment of poor-risk neuroblastoma patients with high-dose chemotherapy and autologous peripheral stem cell rescue. Cohn SL; Moss TJ; Hoover M; Katzenstein HM; Haut PR; Morgan ER; Green AA; Kletzel M Bone Marrow Transplant; 1997 Oct; 20(7):543-51. PubMed ID: 9337055 [TBL] [Abstract][Full Text] [Related]
40. Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support. Bewick M; Chadderton T; Conlon M; Lafrenie R; Morris D; Stewart D; Glück S Bone Marrow Transplant; 1999 Aug; 24(4):377-84. PubMed ID: 10467326 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]